Androgen receptor (AR-V7 splice variant-specific) antibodies

In advanced prostate cancer, androgen receptor splice variant 7 (AR-V7) is the most abundant androgen receptor mRNA splice variant and generates a protein lacking the ligand-binding domain with resultant ligand-independent, constitutive transcriptional activity. Mechanistic and clinical studies have shown that AR-V7 is not only a biomarker for resistance to second-generation androgen receptor signaling inhibitors, but also functions in driving that phenotype (Ref. 1, 2). This makes AR-V7 a crucial marker for therapeutic decision-making by directing clinicians to use taxane therapy in cases of high-risk prostate cancer.

Androgen receptor antibodies by GeneTex

GeneTex’s androgen receptor (AR-V7 splice variant) antibodies ([HL1028] (GTX635842) and [HL1240] (GTX636639)) are recombinant rabbit antibodies whose specificity for the AR-V7 mutant was confirmed using extracts from high-/low-expression cell lines (see the data images below). Also offered is a recombinant antibody detecting the full-length androgen receptor (see below; [HL1049] (GTX636021)).

References

1. Zhu Y, Dalrymple SL, Coleman I, et al. Role of androgen receptor splice variant-7 (Ar-v7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. 2020;39(45):6935-6949.
2. Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE. Androgen receptor splice variant, ar-v7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer. Clin Genitourin Cancer. 2020;18(1):1-10.

GeneTex releases high quality recombinant antibodies